-
Depositing Lab
-
Publication
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 30471 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepLV
-
Vector typeLentiviral
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)Stbl3
-
Growth instructionsStbl3
-
Copy numberLow Copy
Gene/Insert
-
Gene/Insert nameCMVenh/gp91/eGFP/cHS4
Cloning Information
- Cloning method Restriction Enzyme
- 5′ sequencing primer pCAG-F
- 3′ sequencing primer EGFP-N (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
From the paper (note that some of these features may not be in this plasmid): All vectors were based on the pRRL-cPPT-hPGK-mcs-WPRE vector, derived from the pRRL-cPPT-hPGKeGFP-WPRE construct. The gp91promoter is the natural myeloid-specific promoter. The CMVenh comes from the peGFP-N1(Clontech, Saint-Germain-en-Laye, France),
the synthetic intron from the pMG5 and the EF1a intron from the pWPI vector http://www.addgene.org/12254 The myeloid-specific enhancer SP107 and SP146 were provided by Senlin Li (Department of Medicine, UTHSCSA, San Antonio, TX, USA). The cHS4 insulator corresponds to the chicken beta-globin 5’-DNase I-hypersensitive
site and was provided by Patrick Salmon (Department of Neuroscience,
Faculty of Medicine, University of Geneva, Switzerland).
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pLV.CMVenh.gp91.eGFP.cHS4 was a gift from Didier Trono (Addgene plasmid # 30471 ; http://n2t.net/addgene:30471 ; RRID:Addgene_30471) -
For your References section:
Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease. Barde I, Laurenti E, Verp S, Wiznerowicz M, Offner S, Viornery A, Galy A, Trumpp A, Trono D. Gene Ther. 2011 May 5. ():. 10.1038/gt.2011.65 PubMed 21544095